IRVINE, Calif., May 8 /PRNewswire-FirstCall/ -- Edwards Lifesciences Corporation (NYSE: EW), the world leader in the science of heart valves, announced that the company will celebrate a number of cardiac surgery milestones and product debuts at the 88th annual meeting of the American Association for Thoracic Surgery (AATS), May 10-14 in San Diego.
Among the milestones marked by Edwards -- which this year celebrates
its 50th anniversary of partnering with clinicians to develop life-saving
innovations -- are:
-- The treatment of more than 1 million patients worldwide with Edwards'
heart valve repair and replacement technologies.
-- The implantation of the Edwards SAPIEN transcatheter aortic heart valve
in more than 1,000 patients worldwide through a series of extensive
clinical trials and feasibility studies in Europe, the U.S. and Canada,
as well as commercial sales in Europe.
-- The start of patient enrollment for transcatheter aortic valve
replacement procedures with the Ascendra transapical delivery system at
participating sites in Edwards' U.S. pivotal trial of the Edwards
SAPIEN valve. Edwards has conditional approval from the U.S. Food and
Drug Administration to perform procedures with both the Ascendra
transapical delivery system and the RetroFlex transfemoral delivery
system at the PARTNER trial sites.
-- Regulatory and reimbursement approval received this week from the
Japanese Ministry of Health for the Carpentier-Edwards PERIMOUNT Magna
pericardial aortic heart valve. As the first and only device of its
kind, this valve combines more than 20 years of clinical experience and
|SOURCE Edwards Lifesciences Corporation|
Copyright©2008 PR Newswire.
All rights reserved